Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03816345 · ClinicalTrials.gov registry record · Phase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

A Phase 1 study of Multiple Sclerosis and Rheumatoid Arthritis, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 1
Development phase
300
Enrollment target
20
Study locations

NCT03816345 is a Phase 1 study of Multiple Sclerosis and Rheumatoid Arthritis that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 300 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03816345, a Phase 1 study of Multiple Sclerosis and Rheumatoid Arthritis, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 1
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions Studied

Multiple Sclerosis Rheumatoid Arthritis Malignant Solid Neoplasm Psoriasis Hematopoietic and Lymphoid Cell Neoplasm Crohn Disease Psoriatic Arthritis Inflammatory Bowel Disease Dermatomyositis Autoimmune Disease

Interventions

  • PROCEDURE Biospecimen Collection
  • BIOLOGICAL Nivolumab

Study Locations (20)

Kansas

  • University of Kansas Clinical Research Center - Fairway
  • HaysMed - Hays
  • University of Kansas Cancer Center - Kansas City
  • Lawrence Memorial Hospital - Lawrence
  • The University of Kansas Cancer Center - Olathe - Olathe
  • University of Kansas Cancer Center-Overland Park - Overland Park
  • University of Kansas Hospital-Indian Creek Campus - Overland Park
  • Mercy Hospital Pittsburg - Pittsburg
  • Salina Regional Health Center - Salina
  • University of Kansas Health System Saint Francis Campus - Topeka
  • University of Kansas Hospital-Westwood Cancer Center - Westwood

California

  • Stanford Cancer Institute Palo Alto - Palo Alto
  • University of California Davis Comprehensive Cancer Center - Sacramento

Connecticut

  • Smilow Cancer Center/Yale-New Haven Hospital - New Haven
  • Yale University - New Haven

Illinois

  • Northwestern University - Chicago
  • University of Chicago Comprehensive Cancer Center - Chicago

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

District of Columbia

  • MedStar Georgetown University Hospital - Washington D.C.

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2019-07-16
Est. Completion 2028-03-30
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03816345

The ClinicalTrials.gov registry entry for NCT03816345 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (49% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.

NCT03816345 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Kansas, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT03816345 about?

NCT03816345 is a clinical study titled "Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer". This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's ...

What is the current status of trial NCT03816345?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2019-07-16. Estimated completion is 2028-03-30.

What conditions does trial NCT03816345 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Rheumatoid Arthritis, Malignant Solid Neoplasm, Psoriasis, Hematopoietic and Lymphoid Cell Neoplasm.

What interventions are being tested in trial NCT03816345?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Nivolumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT03816345?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03816345 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.